New Hope for HIV Cure? Osteoporosis Drug Enters Trial to Fight Latent Virus

CHAPEL HILL, N.C. – August 19, 2026 – In the persistent global search for an HIV cure, researchers are turning to an unexpected source: the pharmacy shelf for bone health. ACTG, a leading global clinical trials network, has launched a study to evaluate whether alendronate, a widely prescribed osteoporosis treatment, can be repurposed to attack the latent HIV reservoir—the hidden, dormant virus that current therapies cannot reach.

The new trial, named STAIR-HIV (Small Trial of Alendronate Impact on the Reservoir of HIV), represents a novel and potentially transformative approach. It aims to harness the drug's unintended side effects on the immune system to “wake up” and expose the virus, making it vulnerable to elimination. If successful, this strategy of repurposing a well-known, safe medication could significantly accelerate the path toward a functional cure for the millions living with HIV worldwide.

“STAIR-HIV seeks to translate years of systematic work into what could become an important component of future cure strategies for people living with HIV,” said ACTG Chair Joseph J. Eron, M.D., of the University of North Carolina. He emphasized that while this trial is not a cure in itself, it is a crucial step. “It will help us understand whether modulating specific metabolic and immunologic pathways in the HIV reservoir can safely move us closer to durable remission, an important goal for the network.”

The Hidden Enemy: Targeting the Latent Reservoir

Antiretroviral therapy (ART) has been a modern medical triumph, transforming HIV from a fatal diagnosis into a manageable chronic condition. By taking daily medication, people living with HIV can suppress the virus to undetectable levels, protecting their immune systems and preventing transmission. However, ART is a lifelong commitment because it cannot eradicate the virus completely.

The primary barrier to a cure is the persistence of the latent HIV reservoir. This reservoir consists of a small population of long-lived immune cells, primarily memory CD4+ T cells, that are infected with HIV but are not actively producing new virus particles. In this dormant state, the virus is invisible to both ART and the body's immune system. If a person stops taking ART, this latent virus inevitably reactivates, leading to a viral rebound.

For years, the leading strategy to eliminate this reservoir has been the “shock and kill” approach. The “shock” phase involves using latency-reversing agents (LRAs) to awaken the dormant virus within the cells, forcing them to produce viral proteins. This unmasks the infected cells, making them visible. The “kill” phase relies on the body’s own immune system or other therapeutic interventions to recognize and destroy these newly activated cells. While conceptually sound, finding an LRA that is both effective and safe has proven to be a major challenge.

A Novel Weapon: How a Bone Drug Could Fight HIV

The STAIR-HIV trial explores alendronate as a new type of LRA with a potentially powerful dual mechanism. Known commercially by brand names like Fosamax, alendronate is a bisphosphonate that works by inhibiting an enzyme in bone cells called farnesyl pyrophosphate synthase (FPPS). This action slows bone loss and is highly effective in treating osteoporosis.

Researchers discovered that this same mechanism has intriguing, non-skeletal effects on the immune system that could be leveraged against HIV. Inhibiting FPPS leads to the accumulation of a molecule called isopentenyl pyrophosphate (IPP). This buildup has two critical consequences.

First, scientific evidence suggests the pathway can trigger the reactivation of latent HIV, providing the “shock” needed to expose the hidden virus. Second, the accumulation of IPP is known to activate a specific type of immune cell called a gamma delta (γδ) T cell. These cells are powerful components of the innate immune system, capable of recognizing and killing infected or cancerous cells. By stimulating these cells, alendronate could simultaneously enhance the “kill” part of the strategy, creating a one-two punch against the reservoir.

This dual-action hypothesis sets alendronate apart from many other LRAs that have been tested, which often focus solely on viral reactivation without providing an accompanying boost to the immune response.

From Observation to Trial: The Genesis of STAIR-HIV

The idea to test alendronate did not come out of thin air. It is the result of years of careful observation and laboratory work building on previous ACTG research. The initial clues emerged from an earlier trial, A5163, which studied alendronate’s effect on bone mass density in people living with HIV—a population at higher risk for osteoporosis.

“Using samples from this trial, we were able to show that alendronate reduced total HIV DNA levels,” explained Natalia Soriano Sarabia, Ph.D., of George Washington University and a co-chair of the new study. “This was a very exciting finding, but because A5163 was not designed to assess these effects, we created STAIR-HIV to do so in a controlled trial with a larger sample size.”

This progression from an unexpected finding in one study to the design of a rigorous, dedicated trial exemplifies the iterative nature of clinical science. The STAIR-HIV trial is designed to provide definitive answers. It will enroll 30 participants who are virally suppressed on ART. Twenty participants will receive a weekly 70 mg oral dose of alendronate, while ten will receive a placebo for 24 weeks. The study design is randomized and double-blind, meaning neither participants nor investigators will know who is receiving the active drug, a gold standard for eliminating bias.

Critically, the trial will intensively monitor the impact on the HIV reservoir not just in the blood, but also in the gut. The gastrointestinal tract is a major site of HIV persistence, and some participants will undergo sigmoidoscopies to allow researchers to directly measure the drug's effect on this key tissue reservoir.

“By testing this treatment under rigorous clinical monitoring, we hope to generate critical data that can guide future combination approaches to an HIV cure,” Dr. Soriano Sarabia added.

A Small Trial with Major Implications

STAIR-HIV is the second study launched under ACTG’s 'Small Clinical Trials Advancing HIV Remission and Cure' program, an initiative designed to rapidly test promising but experimental cure strategies. The small, focused nature of these trials allows for the intensive and complex procedures—like tissue sampling—that are necessary to understand if a strategy is working at a biological level.

While a 30-person trial is not large enough to change clinical practice on its own, its findings will have major implications. If the trial demonstrates that alendronate can safely reduce the intact viral reservoir, it would provide a crucial proof-of-concept. This would almost certainly lead to larger, longer-term studies and investigations into using the drug as part of a combination cure strategy, alongside other immune-based therapies like therapeutic vaccines or broadly neutralizing antibodies.

For the community of people living with HIV, who balance the daily reality of ART with the enduring hope for a cure, such research is watched with a mixture of excitement and cautious optimism. The prospect of using a familiar, well-tolerated drug offers a tangible sense of progress, highlighting how innovative thinking continues to push the boundaries of what is possible in the fight against HIV.